SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development.

Chakraborty, Chiranjib; Bhattacharya, Manojit; Mallick, Bidyut; Sharma, Ashish Ranjan; Lee, Sang-Soo; Agoramoorthy, Govindasamy

INTRODUCTION Protein drug targets play a significant choice in different stages of the drug discovery process. There is an urgent need to understand the drug discovery approaches and protein drug targets (PDT) of SARS-CoV-2, with structural insights for the development of SARS-CoV-2 drugs through targeted therapeutic approach. AREAS COVERED We have described the protein as a drug target class and also discussed various drug discovery approaches for SARS-CoV-2 involving the protein drug targets such as drug repurposing study, designing of viral entry inhibitors, viral replication inhibitors and different enzymes of the virus. We have performed comprehensive literature search from the popular databases such as PubMed Google scholar, Web of Science and Scopus. Finally, we have illustrated the structural landscape of different significant viral proteins (3CLpro or Mpro, PLpro, RdRp, helicase, S protein) and host proteins as drug targets (cathepsin L, furin, TMPRSS2, ACE2). EXPERT OPINION The structural landscape of PDT with their binding pockets, and significant residues involved in binding has been discussed further to better understand the PDT and the structure-based drug discovery for SARS-CoV-2. This attempt will increase more therapeutic options, and combination therapies with a multi-target strategy.